Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
SCI Ventures is a philanthropic investment fund established to develop innovative cures for paralysis. Backed by leading foundations for spinal cord injury in the US and Europe, it operates with the rigor of a venture capital fund. The firm focuses on early-stage companies, particularly in healthcare and biotech, with a specific emphasis on therapies for spinal cord injuries and related conditions.
SCI Ventures invests in companies that are advancing cures for paralysis-related challenges, typically at the Seed and Series A stages. The fund targets technologies that address spinal cord injury and adjacent neurological conditions, emphasizing long-term neural pathway restoration and immediate clinical impact. Investment decisions are guided by community priorities and scientific rigor, focusing on clinical impact, scientific maturity, and potential for financial return.
Notable portfolio companies include NervGen Pharma, developing drug treatments for central nervous system regeneration; Axonis Therapeutics, focused on small molecule drugs for neuron restoration; and Onward Medical, specializing in spinal cord stimulation for movement restoration. Other companies include Healx, an AI-based drug discovery company, and Precision Neuroscience, known for brain-computer interfaces.
Email info@sciventures.com with your deck to pitch SCI Ventures.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.